Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0,Tyr3]Octreotate

#1644

Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs

Aim(s): Identify pitfalls that should be taken into consideration when evaluating the treatment response after PRRT.

Materials and methods: 354 Dutch patients with GEPNETs who were treated with 177Lu-DOTATATE between March 2000 and December 2011 were retrospectively selected. Liver function parameters and chromogranin A were measured before each therapy and in follow-up. Anatomical imaging was performed before therapy and in follow-up after 6 weeks, 3 months and 6 months and thereafter every 6 months.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Brabander T, Van der Zwan W, Teunissen J, Kam B, de Herder W,

Keywords: 177Lu-DOTATATE, PRRT, response evaluation, toxicity,